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Telomere shortening impairs proliferation of transformed cells but also leads to cancer initiation by
inducing chromosomal instability. Here, we discuss recent developments in our understanding of
the role of telomeres in replication stress and how telomerase expression in somatic stem cells
may affect genome integrity control and carcinogenesis.Telomeres are implicated in genome integrity control and carci-
nogenesis. Most research over the last decades focused on the
role of telomere shortening and telomerase activation in this
process. Increasing data indicate that telomeres have additional
functions in genome integrity control mediated by its role in
sensing replication stress. In addition, the role of telomerase
needs to be revisited due to the fact that stem and progenitor
cells express detectable levels of telomerase, and there is
increasing evidence that these cells are the cell type of origin
of cancer formation.
In line with the role of telomere shortening in tumor suppres-
sion, cancer cells were shown to depend on telomere mainte-
nance mechanisms in order to gain immortal proliferation
capacity and to prevent genetic chaos induced by telomere
dysfunction. Two mechanisms of telomere maintenance were
identified in mammalian cells. Most human tumors utilize the
enzyme telomerase, which can synthesize telomeres de novo.
However, 10%–20% of human tumors activate alternative
mechanisms of telomere lengthening (ALT), but the molecular
mechanisms that control the activation of ALT remain incom-
pletely understood. Inhibition of telomerase can reduce tumor
growth in mouse models, but activation of ALT accounts for
tumor relapse (Hu et al., 2012).
Aging-associated telomere shortening can also contribute
to the evolution of genome instability and cancer formation by
inducing chromosome end resection, fusions, and breakage
(Figure 1A). As indicated above, genetically unstable tumor cells
that arise under such circumstances need to reactivate telomere
maintenancemechanisms in order to avoid genetic chaos and to
gain immortal growth. Mouse studies demonstrated that
transient telomere dysfunction, followed by telomerase reactiva-
tion, promotes the development of malignant tumors (Begus-
Nahrmann et al., 2012) by selecting for chromosomal instabilities
and genetic alterations that enhance tumor progression and
metastasis (Ding et al., 2012). Other forms of genome instability
are very similar to telomere loss in exhibiting a dual role in carci-
nogenesis. It appears to be a general theme that tumors rely on
genome instability to arise but can also fall victim to it when there
is too much of it (Cahill et al., 1999).
The choice of DNA repair pathways represents an important
factor determining cellular consequences in response to telo-390 Cell 152, January 31, 2013 ª2013 Elsevier Inc.mere dysfunction. In this context, the activation of nonhomolo-
gous end-joining (NHEJ) pathways leads to chromosomal
fusions, whereas the activation of homology-directed repair
(HDR) can mediate telomerase-independent lengthening of telo-
meres by ALT. Accordingly, the choice of repair responses at
dysfunctional telomeres could influence the evolution of genomic
instability andcancer initiationbypromotingend joiningbut could
also contribute to the capacity of transformed cells to gain
immortal growth capacity by activating ALT (Figure 1A). Because
chromosomal fusions and breakage of fused chromosomes can
contribute to cancer initiation, an understanding of the DNA
repair pathways that induce chromosomal fusions in response
to telomere dysfunction is required to better understand the
role of telomere shortening in cancer initiation in aging tissues.
Telomeric DNA acts in concert with telomere-binding proteins
to form secondary structures (e.g., G-quadruplexes and T-loops)
that suppress the inadequate activation of checkpoints and
DNA repair response at chromosome ends. Experiments on
the conditional deletion of telomere-binding proteins (Trf1 and
Trf2) in mice revealed that these proteins prevent the activation
of six DNA damage response (DDR) pathways: ATM-signaling,
ATR-signaling, DNA resection, HDR, classical nonhomologous
end-joining (c-NHEJ), and alternative NHEJ (alt-NHEJ) (Sfeir
and de Lange, 2012). It remains to be defined which of these
responses are activated at telomeres that lose functionality in
response to telomere shortening. The repair responses that are
induced by telomere deprotection in response to the deletion
of specific telomere-binding proteins can be different from those
induced by telomere dysfunction in response to physiological
telomere shortening. For example, the formation of chromo-
somal fusions in response to Trf2 inhibition is Ligase IV (Lig4)
dependent and thus mediated by c-NHEJ, whereas Lig4 and
DNA-PKcs (two essential components of c-NHEJ) are dispens-
able for chromosome end joining in response to telomere
shortening (Rai et al., 2010). The prominent role of alt-NHEJ in
the formation of chromosomal fusions in response to telomere
shortening quests for a more detailed analysis of alternative
end joining pathways at naturally shortened, dysfunctional telo-
meres. Such studies would be important to better understand
the evolution of chromosomal instability and cancer initiation in
aging tissues.
Figure 1. The Role of Chromosome Ends in Genome Integrity
Control Depends on Telomere Functionality and Telomerase
Expression
(A) During aging and chronic diseases, telomeres lose capping function due to
telomere shortening. Dysfunctional telomeres are largely devoid of telomeric
DNA and telomere-binding proteins, thus inducing DDR, including DNA repair
and checkpoint responses. HDR can contribute to ALT, mediating immortal
proliferation capacity in telomerase-negative human cancers. It is currently
unknown whether HDR and ALT can contribute to maintenance of non-
transformed cells and tissues during aging. Activation of NHEJ leads to
generation of chromosomal fusions, thereby initiating chromosomal instability
and cancer formation, especially when DDR checkpoint responses are
defective. In mammalian cells, chromosome fusions in response to telomere
shortening are mediated by alt-NHEJ. This pathway involves microhomology-
mediated end-joining and is independent of components involved in c-NHEJ.
The choice between different repair pathways is regulated by DNA end
resection at dysfunctional telomeres. 50–30 end resection generates single-
stranded DNA overhangs that inhibit c-NHEJ and activate HDR. 50–30 end
resection may also promote microhomology-dependent alt-NHEJ, leading to
fusion of chromosomes with shortened telomeres.
(B) Young cells and stem cells have long telomeres that cap chromosome ends
by forming secondary structures (e.g., G-quadruplexes and T-loops) in
concert with telomere-binding proteins. Telomere capping impairs the inap-
propriate activation of DDR at chromosome ends that would lead to
chromosomal instability. However, the same structures that protect the
chromosome ends (e.g., G-quadruplexes and T-loops) also represent fragile
sites that are difficult to replicate during S phase of the cell cycle. Specific DNAThe choice of repair responses at DNA breaks is to a great
extent controlled by resection of DNA ends. Resection of the 50
DNA strand inhibits NHEJ and directs repair toward HDR by
generating 30 overhangs. The MRN complex (consisting of
Mre11, NBS, and Rad50), CtIP, and Dna2/BLM initiate resection
followed by progressive resection, which is mediated by Exo1
and BLM. The deletion of inhibitors of end resection (e.g., Ku,
53Bp1, and MDC1) reduces the formation of chromosomal
fusions in mouse models of telomere deprotection induced by
the deletion of telomere-binding proteins (see for example
Dimitrova et al. [2008]). Given the differences in the induction
of NHEJ pathways at deprotected telomeres (in response to
the deletion of telomere-binding proteins) compared to telo-
mere-free ends (in response to critical telomere shortening), it
will be important to evaluate the role of these genes in model
systems of physiological telomere shortening. Exo1 deletion
prolonged survival of telomerase knockout mice by impairing
the formation of single-stranded DNA and the induction of
ATR-dependent DNA damage signals (Schaetzlein et al., 2007).
Of note, Exo1 deletion impaired the rate of anaphase bridges
in telomere-dysfunctional mice, suggesting that Exo1-depen-
dent DNA resection may contribute to the formation of chromo-
somal fusions in response to telomere shortening, possibly
involving the activation of microhomology-mediated alt-NHEJ.
Interestingly, CtIP-dependent end resection was shown to
mediate microhomology-dependent alt-NHEJ in mouse cells,
but it remains to be seen whether this mechanism is involved
in fusion formation of dysfunctional telomeres in response to
telomere shortening (Zhang and Jasin, 2011).
Telomeres in Stem-Cell-Derived Carcinogenesis
There is growing evidence that stem cells often represent the cell
type of origin of cancer formation. A series of recent papers
showed that human stem cells exhibit an age-dependent
increase in mutations showing patterns of clonal evolution
toward tumor formation (see for example Welch et al. [2012]).
In humans, most somatic cells lack telomerase activity, but
somatic stem and progenitor cells express low levels of telome-
rase. Telomere shortening limits the replicative life span of
telomerase-negative cells, but low levels of telomerase in
somatic stem cells likely contribute to the prolonged proliferative
capacity of these cells compared to differentiated somatic cells.
Considering stem cells as the cell type of origin of cancer forma-
tion, the ‘‘classical’’ concept of telomere dysfunction during
cancer initiation followed by telomerase activation needs to be
revisited because somatic stem and progenitor cells express
telomerase to start with.
Several lines of evidence indicate that stem cells have evolved
more stringent mechanisms of genome integrity protection
compared to differentiated proliferating cells. For example, it
was shown that mutation frequencies and frequencies of mitotichelicases have evolved and cooperate with telomere-binding proteins (e.g.,
Trf1) to facilitate telomere replication.
In both scenarios (telomere shortening and telomere replication stress), telo-
merase activation can restore telomere function. Thus, telomerase activity in
stem cells contributes to stabilize stem cell genomes, but it may also increase
the risk of clonal growth when stem cells accumulate mutations.
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recombination in embryonic stem cells are about 100-fold lower
than in adult somatic cells or in isogenic mouse embryonic fibro-
blasts (Cervantes et al., 2002). It is possible that the expression
of telomerase protects aging somatic stem cells from telomere
dysfunction leading to chromosomal instability and an accumu-
lation of procarcinogenic gene mutations. Telomere shortening
leads to an accumulation of chromosomal imbalances in somatic
stem cells, especially when p53-dependent checkpoint
responses are defective (Sperka et al., 2011). There is evidence
that the level of telomerase activity in somatic stem cells is not
sufficient to completely prevent telomere shortening during
aging. Telomere shortening and DNA damage accumulation
occur in human hematopoietic stem and progenitor cells during
aging (for review see Sperka et al. [2012]). According to these
observations, transient telomere dysfunction may occur in aging
stem cells despite low levels of telomerase activity. Compared to
other somatic cells, stem cells may then carry a higher intrinsic
risk to promote immortal growth in response to transient telo-
mere dysfunction, leading to the accumulation of oncogenic
mutations (Figure 1A). The amplification of pre-existing telome-
rase expression in stem cells may be simpler compared to acti-
vation of telomerase in differentiated somatic cells that have
completely silenced the expression of the catalytic subunit of
the enzyme (TERT). Thus, stem cells may carry an increased
capacity to continue to proliferate, to transform, and to gain
immortal growth capacity when exposed to genome instability.
Therefore, more efficient checkpoints may have evolved in
stem cells compared to other somatic cells in order to assure
the elimination of damaged stem cells and to prevent stem-
cell-derived tumorigenesis. Recent studies revealed experi-
mental evidence that DNA damage induces differentiation of
somatic stem cells (Wang et al., 2012). DNA-damage-induced
differentiation of adult stem cells limits self-renewal and removes
damaged cells from the stem cell pool. The contribution of DNA-
damage-induced stem cell differentiation to tumor suppression
remains yet to be investigated.
It is conceivable that the carcinogenic role of telomere
dysfunction followed by telomerase reactivation could proceed
in a different way in stem cells that express telomerase com-
pared to other somatic cells that are telomerase negative. Along
these lines, it would be important to analyze molecular mecha-
nisms that cooperate with telomerase expression in allowing
clonal evolution in response to oncogenic mutation (see below
and Figure 1B).
Replication Stress in Tumor Biology
There is increasing evidence that telomeres can influence aging
and carcinogenesis independent of telomere shortening. This
new function of telomeres involves the fragility of telomeres
(Figure 1B). Due to their specific sequence composition, telo-
meres can form G-quadruplex structures (G4). These structures
are highly stable and are difficult to resolve during replication,
which can cause replication fork stalling and chromosome
fragility. Fragile sites are particularly prone to chromosomal
breakage and recombination events as a result of replication
stress, which may result from inappropriate proliferation signals
such as oncogene activation. There is evidence that telomere-
binding proteins are required for telomere replication. For392 Cell 152, January 31, 2013 ª2013 Elsevier Inc.example, the telomere-binding protein Taz1 and its mammalian
ortholog Trf1 ensure efficient replication of telomeres in Schizo-
saccharomyces pombe and mice (Miller et al., 2006; Sfeir et al.,
2009). A current model indicates that Trf1 acts epistatically of
DNA helicases that have the potential to resolve G4 DNA struc-
tures such as Bloom (BLM), Rtel1, and Pif1.
Interestingly, telomere fragility in response to Trf1 deletion led
to an increase in chromosomal instability and cancer initiation in
the skin epithelium of p53-deficient mice (Martı´nez et al., 2009).
These data suggested that telomere replication stress could
contribute to genome instability and cancer initiation in the
context of defective p53 checkpoints. In contrast to the potential
contribution of telomere replication stress to genome instability
and cancer initiation, telomere replication stress may also serve
as a sensor to limit growth of abnormally proliferating cells in
response to oncogenic stress. Overexpression of oncogenic
H-RASV12 leads to aberrant proliferation, which, in primary
human cells, results in oncogene-induced senescence. Recent
studies revealed that the activation of the RAS oncogene
induces replication fork stalling, fragile telomeres, and an accu-
mulation of DNA damage foci at telomeres in telomerase-nega-
tive human fibroblasts (Suram et al., 2012). Importantly, human
cancer precursor lesions exhibit features of replication stress,
telomeric DDR foci, and senescence, suggesting that replication
stress at telomeres may contribute to the activation of tumor
suppressor checkpoints in response to oncogene activation at
early stages of carcinogenesis. However, invasive cancers
exhibit a diminished accumulation of replication-stress-induced
DDR foci, suggesting that progressive tumor growth selects for
mechanisms that alleviate replication stress.
Together, it is tempting to speculate that telomere fragility
represents yet another type of genome instability exhibiting
a dual role in cancer initiation and suppression. The loss of
shelterin components can lead to replication stress at telomeres
and cancer initiation, whereas the induction of telomere replica-
tion stress in response to oncogene activation contributes to
induction of senescence and the impairment in cancer progres-
sion. However, this hypothesis remains speculative at the
moment, and the recent observations raise several questions.
First, it remains to be elucidatedwhyDNAdamage in response
to oncogenic replication stress specifically accumulates at telo-
meres. G-quadruplexes are present throughout the genome, and
it is unexplained why replication stress specifically leads to telo-
mere fragility. One possible explanation for the accumulation of
telomeric DNA damage in response to replication stress could
be the inhibition of DNA repair response at telomeres. As dis-
cussed above, telomere-binding proteins interact with various
DDR components and suppress their activity at telomeres to
prevent illegitimate recombination and repair events (see above
and Sfeir and de Lange [2012]). Recent studies revealed that the
end protection of telomeres comes with the drawback that DNA
damage inside telomeres is difficult to repair, leading to pro-
longed persistence of DDR in response to DNA damage induc-
tion at telomeres compared to the rest of the genome (Fumagalli
et al., 2012; Hewitt et al., 2012). It is possible that DNA damage,
induced by replication stress, is also affected by the antirepair
activity of telomere-binding proteins and may thus persist over
prolonged periods of time at telomeric sequences compared
to other G-quadruplex-containing sequences (Figure 1B). In
addition, replication timing (a subset of telomeres is replicating
late in S phase) could contribute to the relative sensitivity of telo-
meres to replication stress, although this remains to be analyzed.
Second, aside from the question of telomere-specific vulnera-
bility to replication stress, it will also be important to delineate the
role of telomerase in this context. Telomerase expression did not
suppress the fragile telomere phenotype of human cells in
response to RAS oncogene expression. However, telomerase
activity suppressed the accumulation of intratelomeric DNA
damage foci in response to RAS expression and thus allowed
escape from oncogene-induced senescence (Suram et al.,
2012). These data indicate that telomerase positivity could
enhance the risk of a cell to escape OIS activated by replication
stress at telomeres (Figure 1B). How telomerase expression may
rescue the accumulation of telomeric DNA damage in the setting
of replication stress remains to be defined. Of note, studies in
yeast revealed that telomerase expression could rescue replica-
tion stress at telomeres, induced by the overexpression of Pif1
(Chang et al., 2009). These data suggest that the right stoichiom-
etry of telomerase and G-quadruplex-resolving helicases may
determine the resistance of telomeres to replication stress.
Together, it appears that the most prominent features of telo-
meres, the specific, repetitive nature of G-rich sequences, and
the association of these structures with telomere-binding
proteins also disclose the major drawbacks in repair and replica-
tion of these structures. Whereas the shelterin components
suppress illegitimate recombination and repair of DNA events
at the ends of linear chromosomes, they also suppress efficient
repair of telomeric DNA damage. In addition to its role in limiting
the proliferative life span of human cells, telomeres appear to
serve as sensors of inappropriate replication signals, such as
oncogene activation.
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